- Home
- BEAT vs WHWK Comparison
BEAT vs WHWK Comparison
Compare BEAT & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- WHWK
- Stock Information
- Founded
- BEAT 2015
- WHWK 2007
- Country
- BEAT United States
- WHWK United States
- Employees
- BEAT N/A
- WHWK N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- WHWK Health Care
- Exchange
- BEAT Nasdaq
- WHWK Nasdaq
- Market Cap
- BEAT 55.6M
- WHWK 48.3M
- IPO Year
- BEAT 2021
- WHWK N/A
- Fundamental
- Price
- BEAT $1.81
- WHWK $1.64
- Analyst Decision
- BEAT Buy
- WHWK
- Analyst Count
- BEAT 1
- WHWK 0
- Target Price
- BEAT $8.00
- WHWK N/A
- AVG Volume (30 Days)
- BEAT 55.5K
- WHWK 172.4K
- Earning Date
- BEAT 05-13-2025
- WHWK 05-19-2025
- Dividend Yield
- BEAT N/A
- WHWK N/A
- EPS Growth
- BEAT N/A
- WHWK N/A
- EPS
- BEAT N/A
- WHWK N/A
- Revenue
- BEAT N/A
- WHWK $25,983,000.00
- Revenue This Year
- BEAT N/A
- WHWK $30.85
- Revenue Next Year
- BEAT N/A
- WHWK N/A
- P/E Ratio
- BEAT N/A
- WHWK N/A
- Revenue Growth
- BEAT N/A
- WHWK 6.69
- 52 Week Low
- BEAT $1.45
- WHWK $1.21
- 52 Week High
- BEAT $3.48
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- BEAT 49.82
- WHWK N/A
- Support Level
- BEAT $1.78
- WHWK N/A
- Resistance Level
- BEAT $1.91
- WHWK N/A
- Average True Range (ATR)
- BEAT 0.15
- WHWK 0.00
- MACD
- BEAT 0.02
- WHWK 0.00
- Stochastic Oscillator
- BEAT 44.67
- WHWK 0.00
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.